Meridian Wealth Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-3,821
Closed -$970K 421
2021
Q4
$970K Sell
3,821
-1,802
-32% -$527K 0.1% 160
2021
Q3
$2.16M Sell
5,623
-1,267
-18% -$467K 0.27% 84
2021
Q2
$1.62M Sell
6,890
-2,075
-23% -$371K 0.21% 95
2021
Q1
$1.17M Sell
8,965
-1,143
-11% -$166K 0.17% 120
2020
Q4
$1.05M Buy
+10,108
New +$1.02M 0.17% 112

Other funds holding MRNA

Meridian Wealth Management's MRNA Position: Q1 2022 in Review

Meridian Wealth Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 3,821 shares — an estimated $970K sold.

Meridian Wealth Management first reported a position in MRNA in Q4 2020 and held it in 5 quarters. The position peaked at $2.16M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Meridian Wealth Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Meridian Wealth Management sold 3,821 Moderna shares in Q1 2022, an estimated $970K.
  • Meridian Wealth Management first reported a position in Moderna in Q4 2020 and held it in 5 quarters.
  • Meridian Wealth Management's Moderna position peaked at $2.16M in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Meridian Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.